Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 192 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:08 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $22.7M (5.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 16, 2025 | Jan 11, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Revenue | $403.1M | $332.3M | $116.3M | $75.5M | $78.4M |
| Operating expenses | $342.9M | $277.9M | $271.9M | $255.0M | $305.2M |
| Research and development | $47.9M | $46.2M | $86.1M | $118.9M | $106.0M |
| Selling, general and administrative | $165.8M | $163.1M | $142.5M | $109.1M | $185.0M |
| Operating income | $60.3M | $54.4M | -$155.6M | -$179.5M | -$226.7M |
| Interest expense | – | – | $59.0M | $56.8M | $46.4M |
| Income tax | $1.84M | $0 | $0 | $0 | $0 |
| Net income | -$22.7M | -$51.7M | -$209.2M | -$233.7M | -$269.1M |
| EPS, basic | $-0.11 | $-0.28 | $-2.03 | $-3.52 | $-9.31 |
| EPS, diluted | $-0.11 | $-0.28 | $-2.03 | $-3.52 | $-9.31 |
| Weighted shares, basic | 207.9M | 187.2M | 103.1M | 66.4M | 28.9M |
| Weighted shares, diluted | 207.9M | 187.2M | 103.1M | 66.4M | 28.9M |
| Margins and growth | |||||
| Operating margin | 15.0% | 16.4% | -133.7% | -237.8% | -289.0% |
| Net margin | -5.6% | -15.6% | -179.9% | -309.6% | -343.0% |
| Revenue growth, year over year | +21.3% | +185.7% | +54.1% | −3.8% | −65.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 16, 2025 | Jan 11, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Cash and equivalents | $167.9M | $144.8M | $82.2M | $124.8M | $208.9M |
| Short-term investments | – | – | $0 | $42.1M | $50.4M |
| Accounts receivable | $140.2M | $80.1M | $48.5M | $33.7M | $22.9M |
| Inventory | $105.1M | $94.5M | $65.6M | $35.2M | $34.4M |
| Total current assets | $462.6M | $338.0M | $201.1M | $246.7M | $329.0M |
| Property, plant and equipment | $338.0K | $254.0K | $0 | $164.0K | $664.0K |
| Intangible assets | – | – | – | $56.0K | $56.0K |
| Total assets | $465.9M | $343.8M | $205.8M | $247.9M | $381.6M |
| Accounts payable | $65.1M | $51.6M | $31.7M | $23.0M | $17.6M |
| Total current liabilities | $300.8M | $246.2M | $156.2M | $92.3M | $73.4M |
| Total liabilities | $767.9M | $732.5M | $660.8M | $571.7M | $578.5M |
| Shareholders' equity | -$302.0M | -$388.7M | -$455.0M | -$323.8M | -$196.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 16, 2025 | Jan 11, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Operating cash flow | -$13.1M | -$23.7M | -$135.5M | -$174.8M | -$263.8M |
| Capital expenditures | $0 | $317.0K | – | – | $0 |
| Free cash flow | -$13.1M | -$24.0M | – | – | -$263.8M |
| Stock-based compensation | $9.87M | $12.0M | $12.0M | $15.2M | $24.3M |
| Share buybacks | – | – | – | – | $0 |
| Investing cash flow | $0 | -$317.0K | $42.5M | $8.10M | -$50.5M |
| Financing cash flow | $36.2M | $86.5M | $50.5M | $32.6M | $268.2M |
| Net change in cash | $23.1M | $62.5M | -$42.5M | -$134.1M | -$46.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2.4% | 3.6% | 10.3% | 20.2% | 31.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 30, 2026 | 257.4M | +29.9% | SEC |
| Mar 1, 2026 | 256.8M | +29.8% | SEC |
| Oct 31, 2025 | 239.1M | +21.3% | SEC |
| Aug 8, 2025 | 201.6M | +2.8% | SEC |
| May 1, 2025 | 198.2M | +4.6% | SEC |
| Feb 28, 2025 | 197.8M | +6.9% | SEC |
| Nov 1, 2024 | 197.0M | +73.3% | SEC |
| Aug 1, 2024 | 196.2M | +83.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.